GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: The Journal of Immunology, The American Association of Immunologists, Vol. 187, No. 12 ( 2011-12-15), p. 6550-6563
    Abstract: Homeostasis of peripheral B cell subsets is disturbed during chronic hepatitis C virus (HCV) infection, leading to the occurrence of autoimmunity and B cell lymphoproliferation. However, mechanisms by which HCV causes lymphoproliferation remain controversial. We report in this article on the elevated number of clonal CD21−/lowIgM+CD27+ marginal zone (MZ)-like B cells, which correlates with autoimmunity and lymphoproliferation in HCV patients. We found an increase in autoreactive BCRs using VH1–69 and VH4–34 genes in CD21−/low MZ B cells. CD21−/low MZ B cells showed impaired calcium-mediated signaling, did not upregulate activation markers, and did not proliferate in response to BCR triggering. CD21−/low MZ B cells also were prone to dying faster than their CD21+ counterparts, suggesting that these B cells were anergic. CD21−/low MZ B cells, in contrast, remained responsive to TLR9 stimulation. Gene array analyses revealed the critical role of Early growth response 2 and Cbl-b in the induction of anergy. Therefore, HCV patients who display high frequencies of unresponsive CD21−/low MZ B cells are more susceptible to developing autoimmunity and/or lymphoproliferation. These cells remain in peripheral blood controlled by functional anergy instead of being eliminated, and chronic antigenic stimulation through TLR stimulation may create a favorable environment for breaking tolerance and activating these cells.
    Type of Medium: Online Resource
    ISSN: 0022-1767 , 1550-6606
    RVK:
    RVK:
    Language: English
    Publisher: The American Association of Immunologists
    Publication Date: 2011
    detail.hit.zdb_id: 1475085-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: The Journal of Immunology, The American Association of Immunologists, Vol. 170, No. 4 ( 2003-02-15), p. 1939-1948
    Abstract: Dendritic cells (DCs) are likely to play a key role in immunity against Mycobacterium tuberculosis, but the fate of the bacterium in these cells is still unknown. Here we report that, unlike macrophages (Mφs), human monocyte-derived DCs are not permissive for the growth of virulent M. tuberculosis H37Rv. Mycobacterial vacuoles are neither acidic nor fused with host cell lysosomes in DCs, in a mode similar to that seen in mycobacterial infection of Mφs. However, uptake of the fluid phase marker dextran, and of transferrin, as well as accumulation of the recycling endosome-specific small GTPase Rab11 onto the mycobacterial phagosome, are almost abolished in infected DCs, but not in Mφs. Moreover, communication between mycobacterial phagosomes and the host-cell biosynthetic pathway is impaired, given that & lt;10% of M. tuberculosis vacuoles in DCs stained for the endoplasmic reticulum-specific proteins Grp78/BiP and calnexin. This correlates with the absence of the fusion factor N-ethylmaleimide-sensitive factor onto the vacuolar membrane in this cell type. Trafficking between the vacuoles and the host cell recycling and biosynthetic pathways is strikingly reduced in DCs, which is likely to impair access of intracellular mycobacteria to essential nutrients and may thus explain the absence of mycobacterial growth in this cell type. This unique location of M. tuberculosis in DCs is compatible with their T lymphocyte-stimulating functions, because M. tuberculosis-infected DCs have the ability to specifically induce cytokine production by autologous T lymphocytes from presensitized individuals. DCs have evolved unique subcellular trafficking mechanisms to achieve their Ag-presenting functions when infected by intracellular mycobacteria.
    Type of Medium: Online Resource
    ISSN: 0022-1767 , 1550-6606
    RVK:
    RVK:
    Language: English
    Publisher: The American Association of Immunologists
    Publication Date: 2003
    detail.hit.zdb_id: 1475085-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    The American Association of Immunologists ; 2022
    In:  The Journal of Immunology Vol. 208, No. 1_Supplement ( 2022-05-01), p. 160.14-160.14
    In: The Journal of Immunology, The American Association of Immunologists, Vol. 208, No. 1_Supplement ( 2022-05-01), p. 160.14-160.14
    Abstract: Low-dose (LD) IL-2 is a promising strategy to boost Tregs in patient with autoimmune diseases. This therapeutic strategy would benefit by identifying biomarkers that are highly and selectively responsive to IL-2R signaling in Treg and Teff cells. To initially address this point, RNA-seq was used to screen for genes that are induced in CD4+ Foxp3+ Treg and CD4+ CD45RO+ T effector/memory (TEM) cells from normal subjects in vitro by IL-2R, but not TCR/CD28, signaling. CEACAM1 was identified as a candidate gene in Tregs 4 and 24 hours post-stimulation. However, CEACAM1 was optimally upregulated in Treg and TEM cells after an extended 5 day culture with anti-CD3/CD28 and IL-2. Notably, anti-IL-2 essentially completely inhibited this upregulation, indicating that CEACAM1 expression was strictly IL-2 dependent. Tregs were shown to express the long isoform of CEACAM1 with inhibitory ITIM domains and the ITIMs may be functionally active as most in vitro activated CEACAM1+ Tregs did not express Ki67. To assess CEACAM1 as an IL-2-dependent biomarker during LD-IL-2 therapy, CD25 and CEACAM1 were evaluated at the protein and RNA levels for patient samples from eight distinct autoimmune diseases. In all samples, CEACAM1 was upregulated after a 5-day induction course of LD-IL-2 in Tregs but not TEM cells. This finding correlated with the effect of LD-IL-2 on CD25. CEACAM1 levels returned to baseline 14 days post-LD-IL-2 treatment. After the induction course of LD-IL-2, most CEACAM1+ Tregs were Ki67−, consisting with an inhibitory role for CEACAM1. Collectively, our findings indicate that CEACAM1 is a biomarker for LD-IL-2 therapy whose expression is highly dependent on IL-2R signaling and suggest that CEACAM1 may function to regulate Treg homeostasis. Supported by R01AI131643   
    Type of Medium: Online Resource
    ISSN: 0022-1767 , 1550-6606
    RVK:
    RVK:
    Language: English
    Publisher: The American Association of Immunologists
    Publication Date: 2022
    detail.hit.zdb_id: 1475085-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...